102767-31-7

Basic information

• Product Name: (S)-N-(1-aMino-1-oxobutan-2-yl)-4-chlorobutanaMide
• Synonyms: (S)-N-(1-aMino-1-oxobutan-2-yl)-4-chlorobutanaMide;LevetiracetaM Related CoMpound A;Levetiracetam Related Compound A (20 mg) ((S)-N-(1-amino-1-oxobutan-2-yl)-4-chlorobutanamide);(S)-N-[1-(AMinocarbonyl)propyl]-4-chlorobutanaMide;N-[(1S)-1-(AMinocarbonyl)propyl]-4-chlorobutanaMide;Levetiracetam USP RC A;Levetiracetam Impurity E
• CAS NO: 102767-31-7
• Molecular Formula: C₈H₁₅ClN₂O₂
• Molecular Weight: 207
• Mol File: 102767-31-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 453.2±30.0 °C(Predicted)
• Appearance: /
• Density: 1.154±0.06 g/cm3(Predicted)
• PKA: 14.54±0.46(Predicted)
• BRN: 13476773
• CAS DataBase Reference: (S)-N-(1-aMino-1-oxobutan-2-yl)-4-chlorobutanaMide(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N-(1-aMino-1-oxobutan-2-yl)-4-chlorobutanaMide(102767-31-7)
• EPA Substance Registry System: (S)-N-(1-aMino-1-oxobutan-2-yl)-4-chlorobutanaMide(102767-31-7)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN 2811 6.1 / PGIII
• Hazardous Substances Data: 102767-31-7(Hazardous Substances Data)

Usage

Description

(S)-N-(1-aMino-1-oxobutan-2-yl)-4-chlorobutanaMide, also known as Levetiracetam related compound A, is a chemical compound with the molecular formula C8H14ClNO3. It is structurally related to Levetiracetam (L331500), a widely used antiepileptic drug. (S)-N-(1-aMino-1-oxobutan-2-yl)-4-chlorobutanaMide exhibits potential therapeutic properties and is being investigated for its applications in various fields.

Uses

Used in Pharmaceutical Industry:
(S)-N-(1-aMino-1-oxobutan-2-yl)-4-chlorobutanaMide is used as a potential therapeutic agent for the treatment of neurological disorders, particularly epilepsy. Its structural similarity to Levetiracetam suggests that it may have similar mechanisms of action, which could help in controlling seizures and managing the symptoms of epilepsy.
Used in Research and Development:
In the field of pharmaceutical research and development, (S)-N-(1-aMino-1-oxobutan-2-yl)-4-chlorobutanaMide serves as a valuable compound for studying the structure-activity relationship of Levetiracetam and its analogs. This can lead to the discovery of new drugs with improved efficacy and safety profiles for the treatment of various neurological conditions.
Used in Drug Delivery Systems:
Similar to Gallotannin, (S)-N-(1-aMino-1-oxobutan-2-yl)-4-chlorobutanaMide can also be incorporated into novel drug delivery systems to enhance its bioavailability, delivery, and therapeutic outcomes. This may involve the use of organic or metallic nanoparticles as carriers, which can improve the compound's solubility, stability, and targeting capabilities.

Upstream product

• 7324-11-0 (S)-2-amino-butanamide 
• 4635-59-0 4-Chlorobutanoyl chloride 
• 53726-14-0 (S)-2-amino-butanamide hydrochloride 

Downstream Products

• 102767-28-2 levetiracetam 

Relevant articles and documents

Synthesis process of levetiracetam

The invention relates to the technical field of pharmaceutical preparation, in particular to a preparation method of an antiepileptic drug. The synthesis process of levetiracetam designed by the invention takes (S)-2-(4-chlorobutyramide) butyric acid as an initial raw material, pyridine as an alkali and (Boc)2O as an activating reagent of carboxylic acid, an ammonium salt is added to prepare (S)-2-(4-chlorobutyramide) butyramide, and finally a cyclization reaction is carried out in the presence of alkali to obtain levetiracetam. The process does not need chemical resolution, does not use highly toxic or corrosive chemical reagents, is simple to operate, mild in conditions, environment-friendly and high in finished product quality, and is suitable for industrial production.

PROCESSES FOR THE PREPARATION OF LEVETIRACETAM, ITS INTERMEDIATE AND THE USE OF LEVETIRACETAM IN PHARMACEUTICAL COMPOSITIONS

The invention relates to processes for the preparation of (S)-2-aminobutanamide of Formula I, and to the use of the compound of Formula I as intermediate for the preparation of levetiracetam of Formula (II).The invention also relates to a process for the preparation of levetiracetam and pharmaceutical compositions that include the levetiracetam.

(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide

(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide, its preparation and pharmaceutical compositions containing the same. It can be prepared either by reacting (S)-alpha-ethyl-2-oxo-1-pyrrolidineacetic acid successively with an alkyl haloformate and with ammonia, or, by cyclizing an (S)-2-aminobutanamide of the formula X--CH2 CH2 --Y--NHCH(C2 H5)CONH2 wherein Y is a --CH2 -- radical when X represents a ZOOC-- radical and Y is a --CO-- radical when X represents a HalCH2 -- radical, Z being a C1 -C4 alkyl radical and Hal a halogen atom. This laevorotatory enantiomer has been found to have significantly higher protective activity against hypoxia and ischemia than the corresponding racemate.